Security key
53630L100
LIPELLA PHARMACEUTICALS INC. - Common Stock (LIPO)
CUSIP: 53630L100
Q3 2024 13F Holders as of 30 Sep 2024
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 84,795
- Total 13F value
- $39,706
- Share change
- -545,496
- SEC-reported price per share
- $0.47
- Number of holders
- 5
- Value change
- -$245,427
- Number of buys
- 2
- Number of sells
- 5
- Shares outstanding
- 1,231,122
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2024
Institutions
5
Top holders
5
LIPO full security history
Ownership snapshot
Full 13F holder table
LIPELLA PHARMACEUTICALS INC. SEC filings
LIPELLA PHARMACEUTICALS INC. company facts
Broader feeds
Ownership snapshot
Top reported holders of LIPO - LIPELLA PHARMACEUTICALS INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
SABBY MANAGEMENT, LLC
Disclosed value leader
Michael B. Chancellor
Comparable rows
7/15
Latest evidence
30 Jun 2024
13F
3/4/5
Lead comparable stake: 44%
8 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
SABBY MANAGEMENT, LLC leads the comparable SEC ownership view at 44%.
7 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens SABBY MANAGEMENT, LLC's linked filing trail.
Comparable ownership
Top 5
SABBY MANAGEMENT, LLC
44%
VANGUARD GROUP INC
2.8%
GEODE CAPITAL MANAGEMENT, LLC
2.1%
TWO SIGMA INVESTMENTS, LP
1.1%
UBS Group AG
0.71%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| SABBY MANAGEMENT, LLC |
13F
Company
|
44%
|
$243,113
540,250 shares
|
— | 30 Jun 2024 |
| VANGUARD GROUP INC |
13F
Company
|
2.8%
|
$15,534
34,520 shares
|
— | 30 Jun 2024 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
2.1%
|
$12,111
25,998 shares
|
— | 30 Jun 2024 |
| TWO SIGMA INVESTMENTS, LP |
13F
Company
|
1.1%
|
$5,843
12,984 shares
|
— | 30 Jun 2024 |
| UBS Group AG |
13F
Company
|
0.71%
|
$3,949
8,775 shares
|
— | 30 Jun 2024 |
| Tower Research Capital LLC (TRC) |
13F
Company
|
0.63%
|
$3,473
7,718 shares
|
— | 30 Jun 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
5
Shares
84,795
Rows available
5
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
7
Q3 2024 holders
5
Holder diff
-2
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 value | Q3 2024 value | Value change | Value Chg % |
|---|